ВАК (Россия)
РИНЦ (Россия)
EBSCO
Регистрационное агентство DOI (США)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

ДИФФЕРЕНЦИРОВАННЫЙ ПОДХОД К НАЗНАЧЕНИЮ ИНГИБИТОРОВ ДИПЕПТИДИЛПЕПТИДАЗЫ-4

Скачать статью в PDF
Номер журнала: 
1
Год издания: 
2016

А. Вербовой, доктор медицинских наук, профессор, Ю. Долгих, кандидат медицинских наук, А. Пашенцева, кандидат медицинских наук Самарский государственный медицинский университет E-mail: yulyadoll@mail.ru

Сахарный диабет – одно из наиболее распространенных заболеваний. Для его лечения применяют препараты разных групп. Относительно новые представители сахароснижающих препаратов – ингибиторы дипептидилпептидазы-4. Проанализированы их эффективность и безопасность у пациентов с нарушением функции печени и почек, а также их влияние на риск развития сердечно-сосудистых осложнений.

Ключевые слова: 
клиническая фармакология
сахарный диабет типа 2
ингибиторы дипептидилпептидазы-4
инкретины
сердечно-сосудистый риск

Для цитирования
Вербовой А., Долгих Ю., Пашенцева А. ДИФФЕРЕНЦИРОВАННЫЙ ПОДХОД К НАЗНАЧЕНИЮ ИНГИБИТОРОВ ДИПЕПТИДИЛПЕПТИДАЗЫ-4 . Врач, 2016; (1): 25-29


It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. International Diabetes Federation. The Diabetes Atlas, fourth edition (2011). 1. http://www.idf.org/diabetesatlas.
  2. Stratton I., Adler A., Neil H. et al. Association of glycaemia with macrovascular 2. and microvascular complications of type 2 dia-betes (UKPDS 35): prospective observational study // BMJ. – 2000; 321: 405–12.
  3. Вербовой А.Ф., Барабанова Н.А. Фармакоэпидемиологический анализ терапии сахарного диабета 2-го типа в амбулаторной практике // Пробл. эндо-кринол. – 2009; 55 (4): 3–6.
  4. Holst J. The physiology and pharmacology of incretins in type 2 diabetes // Diabet. Obes. Metab. – 2008; 10 (Suppl. 3): 14–21.
  5. Романов Г.Н. Ингибиторы дипептидилпептидазы-4: новые возможности эффективной и безопасной оптимизации углеводного обмена у пациентов с сахарным диабетом 2-го типа // Мед. новости. – 2013; 3: 15–9.
  6. Wei Y., Mojsov S. Tissue-specifi c expression of the human receptor for glucagon-like peptide 1: brain, heart and pancreatic forms have the same deduced amino acid sequences // FEBS Lett. – 1995; 358: 219–24.
  7. Ahren B. GLP-1 and extra-islet effects // Horm. Metab. Res. – 2004; 36: 7. 842–5.
  8. Nikolaidis L., Mankad S., Sokos G. et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion // Circulation. – 2004; 109: 962–5.
  9. Read P., Khan F., Dutka D. Cardioprotection against ischaemia induced by . dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease // Heart. – 2012; 98 (5): 408–13.
  10. Thrainsdottir I., Malmberg K., Olsson A. et al. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure // Diabet. Vasc. Dis. Res. – 2004; 1: 40–3.
  11. Nikolaidis L., Elahi D., Hentosz T. et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy // Circulation. – 2004; 110: 955–61.
  12. Bhashyam S., Fields A., Patterson B. et al. Glucagon like peptide-1 increases myocardial glucose uptake via p38alphaMAP kinase-mediated, nitric oxidedependent mechanisms in conscious dogs with dilated cardiomyopathy // Circulat. Heart Fail. – 2010; 3: 512–21.
  13. Joseand T., Inzucchi S. Cardiovascular effects of the DPP-4 inhibitors // Diabet. Vasc. Dis. Res. – 2012; 9 (2): 109–16. Инструкция по медицинскому применению препарата Галвус (вилда-14. глиптин). Регистрационный номер: ЛРС-008119/08.
  14. Ligueros-Saylan M., Foley J., Schweizer A. et al. An assessment of adverse 15. effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials // Diabet. Obes. Metab. – 2010; 12 (6): 495–509.
  15. Macauley M., Hollingsworth K., Smith F. et al. Effect of vildagliptin on 16. hepatic steatosis // Clin. Endocrinol. Metab. – 2015; 100 (4): 1578–85.
  16. Arase Y., Suzuki F., Kobayashi M. et al. Efficacy and safety in sitagliptin 17. therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus // Hepatol. Res. – 2011; 41 (6): 524.
  17. Schweizer A., Dejager S., Foley J. et al. Assessing the cardio-cerebrovascular 18. safety of vildagliptin: metaanalysis of adjudicated events from a large Phase III type 2 diabetes population // Diabet. Obes Metab. – 2010; 12 (6): 485–94.
  18. Инструкция по применению лекарственного препарата для медицин ского применения Онглиза® (саксаглиптин) Регистрационный номер: ЛРС-008697/10. Инструкция по медицинскому применению лекарственного препарата 20. Тражента (линаглиптин). Регистрационное удостоверение: ЛП-001430 от 12.01.2012.
  19. Graefe-Mody U., Rose P., Retlich S. et al. Pharmacokinetics of linagliptin 21. in subjects with hepatic impairment // Br. J. Clin. Pharmacol. – 2012; 74 (1): 75–85.
  20. He Y., Kulmatycki K., Zhang Y. et al. Pharmacokinetics of vildagliptin in 22. patients with varying degrees of renal impairment // Int. J. Clin. Pharmacol. Ther. – 2013; 51 (9): 693–703.
  21. Lukashevich V., Schweizer A., Shao Q. et al. Safety and efficacy of 23. vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial // Diabet. Obes. Metab. – 2011; 13 (10): 947–54.
  22. Schweizer A., Dejager S. Experience with vildagliptin in patients 24. ≥75 years with type 2 diabetes and moderate or severe renal impairment // Diabet. Ther. – 2013; 4 (2): 257–67.
  23. Ito H., Mifune M., Matsuyama E. et al. Vildagliptin is Effective for Glycemic 25. Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis // Diabet. Ther. – 2013; 4 (2): 321–9.
  24. Tani S., Nagao K., Hirayama A. Association between urinary albumin 26. excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: a pilot study // Am. J. Cardiovasc. Drugs. – 2013; 13 (6): 443–50.
  25. Mori H., Okada Y., Arao T. et al. Sitagliptin improves albuminuria in patients 27. with type 2 diabetes mellitus // J. Diab. Invest. – 2014; 5 (3): 313–9. Инструкция по медицинскому применению препарата Янувия (сита-28. глиптин). Регистрационный номер: ЛРС-003200/07.
  26. Kothny W., Lukashevich V., Foley J. et al. Comparison of vildagliptin and 29. sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial // Diabetologia. – 2015; [Epub. ahead of print].
  27. Frederich R., McNeill R., Berglind N. et al. The efficacy and safety of the 30. dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial // Diabetol. Metab. Syndr. – 2012; 4 (1): 36.
  28. Udell J., Bhatt D., Braunwald E. et al. Saxagliptin and cardiovascular 31. outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial // Diabet. Care. – 2015; 38 (4): 696–705.
  29. Экспертный совет по применению нового ингибитора ДПП-4 ТРАЖЕНТА 32. (линаглиптин) в лечении сахарного диабета 2 типа // Сахарный диабет. – 2012; 2: 103–4.
  30. Ito H., Abe M., Antoku S. et al. Comparison of the antidiabetic effects of 33. linagliptin among groups with a normal renal function and a mild or severe renal impairment - retrospective observation study of Japanese patients with type 2 diabetes mellitus // Expert Opin. Pharmacother. – 2015; 16 (3): 289–96.
  31. McGill J., Sloan L., Newman J. et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study // Diabet. Care. – 2013; 36 (2): 237–44.
  32. Groop P., Cooper M., Perkovic V. et al. Linagliptin lowers albuminuria on 35. top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction // Diabet. Care. – 2013; 36 (11): 3460–8.
  33. Cooper M., Perkovic V., McGill J. et al. Kidney Disease End Points in a 36. Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes // Am. J. Kidney Dis. – 2015; [Epub. ahead of print].
  34. Monami M., Dicembrini I., Mannucci E. Dipeptidyl peptidase-4 inhibitors 37. and heart failure: a meta-analysis of randomized clinical trials // Nutr. Metab. Cardiovasc. Dis. – 2014; 24 (7): 689–97.
  35. Wu S., Hopper I., Skiba M. et al. Dipeptidyl peptidase-4 inhibitors and 38. cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants // Cardiovasc. Ther. – 2014; 32 (4): 147–58.
  36. Fadini G., Avogaro A., Degli Esposti L. et al. Risk of hospitalization for heart 39. failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database // Eur. Heart J. – 2015; [Epub. ahead of print].
  37. Kim J., Samson S. Cardiovascular effects of incretin therapy in diabetes 40. care // Metab. Syndr. Relat. Disord. – 2014; 12 (6): 303–10.
  38. Аметов А.С., Кулиджанян Н.К. «Инкретины» в терапии больных сахар-41. ным диабетом 2 типа: фокус на сердечнососудистую недостаточность // Эффективная фармакотерапия. – 2013; Спецвып. №1: 26–31.
  39. Sicras-Mainar A., Navarro-Artieda R. Use of metformin and vildagliptin for 42. treatment of type 2 diabetes in the elderly // Drug Des. Devel. Ther. – 2014; 8: 811–8.
  40. Shimodaira M., Niwa T., Nakajima K. et al. Beneficial effects of vildagliptin 43. on metabolic parameters in patients with type 2 diabetes // Endocr. Metab. Immune Disord. Drug Targets. – 2015 [Epub. ahead of print].
  41. Аметов А.С., Карпова Е.В. Эффективное и безопасное управление 44. сахарным диабетом 2 типа при помощи ингибиторов ДПП-4 // Сахарный диа-бет. – 2010; 2: 69–75.
  42. Belice T., Yuce S., Kizilkaya B. et al. Noncardiac Pulmonary Edema induced 45. by Sitagliptin Treatment // J. Family Med. Prim. Care. – 2014; 3 (4): 456–7.
  43. Chen D., Wang S., Mao C. et al. Sitagliptin and cardiovascular outcomes 46. in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study // Int. J. Cardiol. – 2015; 181: 200–6.
  44. Merck. Merck announces the Trial Evaluating Cardiovascular Outcomes with 47. Sitagliptin (TECOS) met primary endpoint. www.mercknewsroom.com/news-release/prescription-medicine-news/merck-announces-trial-evaluating-cardiovascular-outcomes-sit.
  45. Green J., Bethel M., Armstrong P. et al. Effect of Sitagliptin on 48. Cardiovascular Outcomes in Type 2 Diabetes // N. Engl. J. Med. – 2015; [Epub. ahead of print].
  46. Singh T., Vangaveti V., Malabu U. et al. Dipeptidyl peptidase-4 inhibitors 49. and their potential role in the management of atherosclerosis-A review // Diabetes Metab. Syndr. – 2015 [Epub. ahead of print].
  47. Koren S., Shemesh-Bar L., Tirosh A. et al. The Effect of Sitagliptin Versus 50. Glibenclamide on Ar-terial Stiffness, Blood Pressure, Lipids, and Inflammation in Type 2 Diabetes Mellitus Patients // Diabetes Technol. Ther. –2012; [Epub. ahead of print].
  48. Scirica B., Bhatt D., Braunwald E. et al. Saxagliptin and cardiovascular 51. outcomes in patients with type 2 diabetes mellitus // N. Engl. J. Med. – 2013; 369 (14): 1317–26.
  49. Johansen O., Neubacher D., von Eynatten M. et al. Cardiovascular safety 52. with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme // Cardiovasc. Diabetol. – 2012; 11 (3).
  50. Rosenstock J., Marx N., Neubacher D. et al. Cardiovascular safety of 53. linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events // Cardiovasc. Diabetol. – 2015; 14 (1): 57.